EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis

Yao Sun, Shanshan Qin, Lu Wang, Hai Yi, Li Ding, Bo Cai, Na Liu, Yuhang Li, Jiangwei Hu, Zhuoqing Qiao, Fei Li, Daihong Liu und 2 weitere

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06895-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2026. Verfasst von Yao Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutations are associated with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potential cure, but outcomes are suboptimal and risk stratification remains challenging. This multi-center, retrospective study analyzed 66 patients with TP53-mutated AML/MDS who underwent allo-HSCT. The study endpoints included overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and Graft-versus-host disease-free, relapse-free survival (GRFS). After median 1054-day follow-up, 3-year rates for OS, PFS, CIR, NRM, and GRFS were 47.2%, 39.7%, 37.3%, 23%, and 37.4%, respectively. Survival did not differ between AML and MDS. Univariate analysis showed that < 2 somatic myeloid co-mutations predicted inferior OS (3-y OS: 32% vs. 65.9%, p = 0.02) and PFS (27.6% vs. 59.1%, p = 0.01). Age > 50 years adversely affected PFS, and complex karyotype showed a negative trend. Multivariate analysis found no independent factors, likely due to sample size and collinearity. A combined risk factor analysis revealed that patients with ≥ 1 adverse factor (either co-mutations < 2 or complex karyotype) had significantly worse OS (3-y OS: 72.6% vs. 37.2%, p = 0.04) and PFS (3-y PFS: 67.7% vs. 28.9%, p = 0.02) compared to those with neither risk factor. In patients with TP53-mutated AML/MDS undergoing allo-HSCT, a low myeloid co-mutation burden (< 2) is strongly associated with poor outcomes. A composite model integrating co-mutation burden with karyotype may assist in post-transplant risk stratification, offering a practical supplementary parameter when TP53 allelic status is uncertain. This finding requires validation in larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationMutationTumor Suppressor Protein p53HumansRetrospective StudiesFemaleMiddle AgedAdultMaleTransplantation, HomologousPrognosisAgedYoung AdultAdolescent

Stichwörter der Autor:innen

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantation (allo-HSCT)Co-mutationMyelodysplastic syndromesTP53 mutation

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Senior Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China.
  • Sichuan Clinical Research Center for Hematological Disease, Chengdu, China.
  • Branch of National Clinical Research Center for Hematological Disease, Chengdu, China.
  • Department of Hematology, Air Force Medical University, Air Force Medical Center, PLA, No.30, Fucheng Road, Beijing, 100142, China.
  • Senior Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China. daihongrm@163.com.

Zitieren

APA

Sun, Y., Qin, S., Wang, L., Yi, H., Ding, L., Cai, B., Liu, N., Li, Y., Hu, J., Qiao, Z., Li, F., Liu, D., Dou, L., & Hu, L. (2026). The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-06895-4

Vancouver

Sun Y, Qin S, Wang L, Yi H, Ding L, Cai B, et al. The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis. Annals of Hematology. 2026. doi:10.1007/s00277-026-06895-4

BibTeX
@article{Sun2026,
  author = {Sun, Yao and Qin, Shanshan and Wang, Lu and Yi, Hai and Ding, Li and Cai, Bo and Liu, Na and Li, Yuhang and Hu, Jiangwei and Qiao, Zhuoqing and Li, Fei and Liu, Daihong and Dou, Liping and Hu, Liangding},
  title = {The prognostic impact of myeloid co-mutation burden in TP53-mutated AML/MDS after allogeneic stem cell transplantation: a multicenter retrospective analysis},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06895-4}
}
Kostenlos starten →